Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on May 8, 2025

2025 Special Offers for Medical Workers to Celebrate Their Dedication to the Healthcare System

2025 Special Offers for Medical Workers to Celebrate Their Dedication to the Healthcare System

PORTLAND, Ore., May 08, 2025 (GLOBE NEWSWIRE) -- SheerID, the leading verification platform for high-impact consumer groups, is honoring nurses, all medical workers and first responders in 2025 with access to exclusive savings from more than 80 leading …

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson

Southlake, TX, May 08, 2025 (GLOBE NEWSWIRE) -- HeartSciences Inc. (Nasdaq:HSCS) ("HeartSciences" or the "Company"), an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier …

Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers

Truveta leads a new era in cancer research with the most complete, representative, and timely real-world data on all cancers

BELLEVUE, Wash., May 08, 2025 (GLOBE NEWSWIRE) -- Today, Truveta announced a new era in cancer research with more than 7 million oncology patient journeys spanning more than 100 cancer types, delivering an unprecedented breadth of regulatory grade data to …

Wellgistics Health Secures $50M ELOC facility for XRP Treasury Reserve & Real-Time Payments Infrastructure and other general ops

Wellgistics Health Secures $50M ELOC facility for XRP Treasury Reserve & Real-Time Payments Infrastructure and other general ops

Tampa, FL, May 08, 2025 (GLOBE NEWSWIRE) -- Wellgistics Health, Inc. (NASDAQ: WGRX), a technology-first pharmaceutical distribution and healthcare infrastructure company, today announced a new initiative to pioneer the use of XRP, a blockchain-based …

Best Steroids For Cutting: Top Anabolic Steroid Stack For Cutting Cycles To Get Ripped And Shredded Muscles - Crazybulk

Best Steroids For Cutting: Top Anabolic Steroid Stack For Cutting Cycles To Get Ripped And Shredded Muscles - Crazybulk

New York City, May 08, 2025 (GLOBE NEWSWIRE) -- When individuals commit to bodybuilding, they often find adding mass relatively straightforward. However, they encounter a significant challenge during the cutting phase due to its demanding nature and the …

Best Legal Steroids (USA): Top 4 Anabolic Steroids For Muscle Growth & Natural Bodybuilding By Wolfson Brands

Best Legal Steroids (USA): Top 4 Anabolic Steroids For Muscle Growth & Natural Bodybuilding By Wolfson Brands

Glasgow, May 08, 2025 (GLOBE NEWSWIRE) -- Introduction: Legal Steroids – The Safer Path to Muscle Growth In the world of bodybuilding and fitness, the pursuit of muscle growth, strength, and a shredded physique often leads people to explore supplements …

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists

OCALA, Fla., May 08, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (OTC Pink: AIMI) (“AIM” or the “Company”) today announced the presentation of clinical trial data involving AIM’s drug Ampligen by Pawel Kalinski, MD, PhD, at the recent …

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

GRI Bio’s Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) 

The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient enrollment for the 6-week interim analysis (N=24) and over …

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

Senti Bio Releases Mechanism of Action Video for First-in-Class Off-the-Shelf Logic Gated Selective CD33 OR FLT3 NOT EMCN CAR NK Cell Therapy, SENTI-202

Access video here SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its …

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

Vor Bio Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, based on currently available clinical data from its key clinical programs and a challenging fundraising …

HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025

HepaRegeniX Scientific Founder Covers HRX-215 Development and Clincial Data in Plenary at the European Association for the Study of the Liver Congress 2025

Prof. Lars Zender’s featured talk described HepaRegeniX’s lead candidate and its potential in increasing liver regeneration, from initial target discovery and drug development towards Phase Ia clinical trial results Tuebingen, Germany, May 8, 2025 – …

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Adial Pharmaceuticals Granted End of Phase 2 Meeting from the U.S. Food and Drug Administration

Meeting to Take Place on July 25, 2025 Meeting’s Purpose is To Discuss Upcoming Clinical Development Plan and Protocol Designs GLEN ALLEN, Va., May 08, 2025 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a …

Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGR | MarketsandMarkets™.

Precision Medicine Market worth $246.66 billion by 2029 with 11.1% CAGR | MarketsandMarkets™.

Delray Beach, FL, May 08, 2025 (GLOBE NEWSWIRE) -- The global precision medicine market, valued at US$132.46 billion in 2023, is forecasted to grow at a robust CAGR of 11.1%, reaching US$145.53 billion in 2024 and an impressive US$246.66 billion by 2029. …

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

ALX Oncology Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following announcement of prioritized development strategy for evorpacept in combination with anti-cancer antibodies at R…

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset

New patent filing secures composition of matter protection for AZD5904, a potent myeloperoxidase inhibitor in Conduit’s pipeline, unlocking up to 20 years of new IP runway and enabling enhanced formulation strategies to target a broad range of diseases. …

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

Lifeward Completes Research Program with Israeli Human-Robot Interaction Consortium to Integrate Artificial Intelligence and Exoskeletons

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 08, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …

Exagen Inc. Prices Public Offering of Common Stock

Exagen Inc. Prices Public Offering of Common Stock

CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock …

Arialief Complaints Exposed: 2025 User Reviews Analyzed and Verified

Arialief Complaints Exposed: 2025 User Reviews Analyzed and Verified

FINDLAY, Ohio, May 08, 2025 (GLOBE NEWSWIRE) -- What is Arialief? Arialief is a premium natural dietary supplement formulated to support joint health, reduce chronic inflammation, and improve mobility in people suffering from musculoskeletal discomfort. It …

STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

STRATA Skin Sciences to Participate in the D. Boral Capital Inaugural Global Conference

HORSHAM, Pa., May 08, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic …

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

Yamo Pharma Presents Statistically Significant Phase 2 Autism Results for L1-79 at INSAR 2025

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Yamo Pharmaceuticals, a clinical-stage biopharmaceutical company dedicated to treating the core symptoms of autism spectrum disorder (ASD), today announced positive Phase 2 results for L1-79, presented at the …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service